|
|
| (One intermediate revision by one other user not shown) |
| Line 1: |
Line 1: |
| __NOTOC__
| | #REDIRECT [[Pindolol#Use in Specific Populations]] |
| {{Pindolol}}
| |
| {{CMG}}
| |
| | |
| ==
| |
| | |
| ====Pregnancy====
| |
| | |
| {{pcat}} '''B'''
| |
| | |
| Studies in rats and rabbits exceeding 100 times the maximum recommended human doses, revealed no embryotoxicity or teratogenicity. Since there are no adequate and well-controlled studies in pregnant women, and since animal reproduction studies are not always predictive of human response, Visken® (pindolol), as with any drug, should be employed during pregnancy only if the potential benefit justifies the potential risk to the fetus.
| |
| | |
| ====Nursing Mothers====
| |
| | |
| Since Visken® (pindolol) is secreted in human milk, nursing should not be undertaken by mothers receiving the drug.
| |
| | |
| ====Pediatric Use====
| |
| | |
| Safety and effectiveness in pediatric patients have not been established.<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = VISKEN (PINDOLOL) TABLET [NOVARTIS PHARMACEUTICALS CORPORATION] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=07fe9cc3-1ef2-420c-b45d-7f1e894b6ef9 | publisher = | date = | accessdate = }}</ref>
| |
| | |
| ==References==
| |
| {{Reflist}}
| |
| | |
| {{FDA}}
| |
| | |
| [[Category:Cardiovascular Drugs]]
| |
| [[Category:Beta blockers]]
| |
| [[Category:Drugs]]
| |